A Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic Malignancies

A Phase I Single Arm,Open-label,Multiple Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic Malignancies

Evaluate the safety, pharmacokinetics and efficacy of HEC89736 in patients with Relapsed or Refractory B-cell Hematologic Malignancies

Inclusion Criteria:

• Age is over 18 years old
• Histologically or cytologically diagnosed patients with recurrent or refractory B-cell malignancies
• ECOG performance status (PS) 0 ~ 1
• Expected survival of > or = 3 months

Exclusion Criteria:

• The use of PI3Ks as the target of anti-tumor drugs progress (due to intolerance group)
• Received any other anti-cancer treatment within 4 weeks
• Unable to swallow, chronic diarrhea and intestinal obstruction, there are many factors that affect drug use and absorption
• Allergy, or known to have a history of allergy to the drug components